Literature DB >> 10449126

Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group.

L H Visser1, P I Schmitz, J Meulstee, P A van Doorn, F G van der Meché.   

Abstract

OBJECTIVE: To determine the influence of clinical, laboratory, and electrodiagnostic factors on the prognosis of Guillain-Barré syndrome (GBS).
BACKGROUND: Identification of prognostic factors may lead to better selection of patients with a poor prognosis for new therapeutic trials.
METHODS: The authors studied 147 patients with GBS who participated in the Dutch GBS trial comparing the effect of IV immunoglobulins with plasma exchange (PE). Outcome was measured at 8 weeks because half of the patients had recovered independent locomotion by then and at 6 months, the endpoint of the study.
RESULTS: Multivariate logistic regression revealed the following factors predicting outcome (inability to walk independently) at 8 weeks: a preceding gastrointestinal illness (yes, no), age (> or =50, <50 years), Medical Research Council sum score (<40, > or =40) at the start of treatment, and-described for the first time-a recent cytomegalovirus (CMV) infection (yes, no). At 6 months, the same clinical factors were found, but an initial rapid progression of weakness also appeared to be a prognostic factor. Analysis of treatment interactions revealed that the effect of diarrhea was more pronounced in the PE-treated group.
CONCLUSIONS: The main predictors of outcome in GBS are clinical factors. Diarrhea is an important poor predictor of outcome, especially for the PE-treated group, and a recent CMV infection predicts delayed early recovery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449126     DOI: 10.1212/wnl.53.3.598

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

Review 1.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

Review 2.  Respiratory dysfunction in Guillain-Barré Syndrome.

Authors:  David Orlikowski; Hélène Prigent; Tarek Sharshar; Frédéric Lofaso; Jean Claude Raphael
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

3.  Recovery patterns and long term prognosis for axonal Guillain-Barré syndrome.

Authors:  A Hiraga; M Mori; K Ogawara; S Kojima; T Kanesaka; S Misawa; T Hattori; S Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

Review 4.  Plasma exchange for Guillain-Barré syndrome.

Authors:  Sylvie Chevret; Richard Ac Hughes; Djillali Annane
Journal:  Cochrane Database Syst Rev       Date:  2017-02-27

5.  Long-term outcome of Guillain-Barré syndrome.

Authors:  S Koeppen; K Kraywinkel; T E Wessendorf; C E Ehrenfeld; M Schürks; H C Diener; C Weimar
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

6.  Cytomegalovirus disease with Guillain-Barré syndrome in a cadaver renal allograft recipient: cause or coincidence.

Authors:  Sai Ram R Keithi-Reddy; Rajasekhara M Chakravarthi; Shaista M Hussaini; Rohini R Venkatapuram; J M K Murthy
Journal:  Int Urol Nephrol       Date:  2007-04-21       Impact factor: 2.370

7.  An electrophysiological classification associated with Guillain-Barré syndrome outcomes.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Kiichi Unoda; Kazushi Yamane; Yoshimitsu Doi; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

Review 8.  Cerebrospinal fluid biomarkers in Guillain-Barré syndrome--where do we stand?

Authors:  Johannes Brettschneider; Axel Petzold; Sigurd Süssmuth; Hayrettin Tumani
Journal:  J Neurol       Date:  2009-02-16       Impact factor: 4.849

Review 9.  Guillain-Barré syndrome and variants.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-02-19       Impact factor: 3.806

10.  Guillain-barré syndrome.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.